Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy

References

• Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013;110:3011–6.
   PubMed Web of Science ®Google Scholar
• Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89:365–74.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090–8.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27:1275–82.
   PubMed Web of Science ®Google Scholar
• Harada Y, Harada H. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. J Cell Biochem. 2011; 112:425–32.
   PubMed Web of Science ®Google Scholar
• Link CD. Genomics of AML: clinical applications, 53rd ASH Annual Meeting and Exsposition. St. Louis, MO: Washington University; 2011.
   Google Scholar
• Shukron O, Vainstein V, Kündgen A, Germing U, Agur Z. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Am J Hematol. 2012; 87:853–60.
   PubMed Web of Science ®Google Scholar
• Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer. 2013;133:260–5.
   PubMed Web of Science ®Google Scholar
• Yang J, Qian J, Lin J, Yang XF, Qian W, Chen Q, et al. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations. Genet Test Mol Biomarkers. 2013;17:342–7.
   PubMed Web of Science ®Google Scholar
• Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, et al. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood. 2014; 123:3336–43.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120: 3106–11.
   PubMed Web of Science ®Google Scholar
• Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460:904–8.
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27:6109–16.
   PubMed Web of Science ®Google Scholar
• Kao HW, Sanada M, Liang DC, Lai CL, Lee EH, Kuo MC, et al. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. Neoplasia. 2011;13:1035–42.
   PubMed Web of Science ®Google Scholar
• Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, et al. Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Leuk Res. 2010; 34:1539–42.
   PubMed Web of Science ®Google Scholar
• Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010; 115:2891–900.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111: 2527–37.
   PubMed Web of Science ®Google Scholar
• Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113:5250–3.
   PubMed Web of Science ®Google Scholar
• Pinheiro RF, de Sá Moreira E, Silva MR, Alberto FL, Chauffaille Mde L. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183:89–93.
   PubMed Web of Science ®Google Scholar
• Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88:56–9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang M, Yang L, Xiao Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res. 2007;31:109–11.
   PubMed Web of Science ®Google Scholar
• Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011;135:62–9.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013; 27:2081–3.
   PubMed Web of Science ®Google Scholar
• Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45:942–6.
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113:3331–40.
   PubMed Web of Science ®Google Scholar
• Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007;20:29–37.
   PubMed Web of Science ®Google Scholar
• Gale RP, Bennett JM. Are myelodysplastic syndromes and acute myeloid leukemia one disease? Leuk Res. 2009;33:351–4.
   PubMedGoogle Scholar
• Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88:831–7.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Matsuyama T, Ueda M, Suzuki T, Ozaki K, Mori M, et al. Predictive factors of response and survival following chemotherapy treatment in acute myeloid leukemia progression from myelodysplastic syndrome. Intern Med. 2009;48:1629–33.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Issa JP, Garcia-Manero G, O’Brien S, Pierce S, Shan J, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115:5746–51.
   PubMed Web of Science ®Google Scholar
• Corrêa de Souza D, de Souza Fernandez C, Camargo A, Apa AG, Sobral da Costa E, Bouzas LF, et al. Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. Biomed Res Int. 2014;2014:542395.
   PubMedGoogle Scholar
• Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7.
   PubMedGoogle Scholar
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116: 354–65.
   PubMed Web of Science ®Google Scholar
• Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, et al. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol. 2011;24:384–9.
   PubMed Web of Science ®Google Scholar
• Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am J Clin Pathol. 2011; 136:282–8.
   PubMed Web of Science ®Google Scholar
• Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012;87:245–50.
   PubMed Web of Science ®Google Scholar
• Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012;118:2879–88.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q- syndrome. Blood. 2010;116:5803–11.
   PubMed Web of Science ®Google Scholar
• Zemanova Z, Michalova K, Buryova H, Brezinova J, Kostylkova K, Bystricka D, et al. Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. Leuk Res. 2014;38:537–44.
   PubMed Web of Science ®Google Scholar
• Stoddart A, Fernald AA, Wang J, Davis EM, Karrison T, Anastasi J, et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014; 123:1069–78.
   PubMedGoogle Scholar
• Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51:1086–92.
   PubMed Web of Science ®Google Scholar
• Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87:1010–16.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160:660–72.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol. 2011;153:568–81.
   PubMed Web of Science ®Google Scholar
• Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119;2114–21.
   PubMed Web of Science ®Google Scholar
• McDevitt MA. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol. 2012;39: 109–22.
   PubMed Web of Science ®Google Scholar
• Greenberg PL. Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol. 2012;34:215–22.
   PubMed Web of Science ®Google Scholar
• Mahmud M, Stebbing J. Epigenetic modifications in AML and MDS. Leuk Res. 2010;34:139–40.
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76:23–32.
   PubMed Web of Science ®Google Scholar
• Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, et al. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma. 2012;59:168–74.
   PubMed Web of Science ®Google Scholar
• Li L, Sun XM. Research on molecular markers for epigenetic changes in myeloid malignancies. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013;30:687–92.
   PubMedGoogle Scholar
• Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363:2424–33.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25:1153–8.
   PubMed Web of Science ®Google Scholar
• Zhu C, Ma Y, Xu XP. Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:873–8.
   PubMedGoogle Scholar
• Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O’Keefe C, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315–25.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4 + CD25high Foxp3 + regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110:847–50.
   PubMed Web of Science ®Google Scholar
• Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol. 2011;38:667–72.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009; 16:70–6.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Barrett AJ. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. Hematol Oncol Clin North Am. 2010;24:331–41.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A, et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood. 2011; 117:2691–9.
   PubMed Web of Science ®Google Scholar
• Mailloux AW, Epling-Burnette PK. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology. 2013;2:e22654.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90:1–50.
   PubMed Web of Science ®Google Scholar
• Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084–95.
   PubMed Web of Science ®Google Scholar
• Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV, et al. Kinetics, function and bone marrow trafficking of CD4 + CD25+ FOXP3 + regulatory T cells in myelodysplastic syndromes (MDS). Leukemia. 2009;23:510–18.
   PubMed Web of Science ®Google Scholar
• Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, et al. Altered naive and memory CD4 + T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009;23:1288–96.
   PubMed Web of Science ®Google Scholar
• Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012;189:3198–208.
   PubMed Web of Science ®Google Scholar
• Al Ustwani O, Francis J, Wallace PK, Ambrus J Jr, Wetzler M. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leuk Res. 2011; 35:e35–6.
   PubMed Web of Science ®Google Scholar
• Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol. 2011;153:664–5.
   PubMed Web of Science ®Google Scholar
• Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol. 2007;14:123–9.
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849–59.
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58:1033–45.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci U S A. 2007;104: 11406–11.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/ Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.
   PubMed Web of Science ®Google Scholar
• Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, et al. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience. Leuk Res. 2011;35:1444–8.
   PubMed Web of Science ®Google Scholar
• Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013;162:74–86.
   PubMed Web of Science ®Google Scholar
• Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, et al. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. Br J Haematol. 2014;166:189–201.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013;27:1072–9.
   PubMed Web of Science ®Google Scholar
• List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28:1033–40.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, et al. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93:429–38.
   PubMed Web of Science ®Google Scholar
• Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012;136:56–68.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Ades L. Review of azacitidine trials in intermediate-2-and high-risk myelodysplastic syndromes. Leuk Res. 2009;33:S7–11.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
   PubMed Web of Science ®Google Scholar
• Xie M, Jiang Q, Xie Y. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1392 participants. Clin Lymphoma Myeloma Leuk. 2015;15:22–28.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD, Komrokji RS. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go? Expert Rev Hematol. 2013;6:251–4.
   PubMed Web of Science ®Google Scholar
• Iizuka H, Yoshimi A, Yamamoto G, Masuda A, Nannya Y, Ichikawa M, et al. Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia. Rinsho Ketsueki. 2013; 54:468–72.
   PubMedGoogle Scholar
• Yamada M, Kuroda H, Jomen W, Yoshida M, Miura S, Abe T, et al. A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts. Gan To Kagaku Ryoho. 2013;40:2593–7.
   PubMedGoogle Scholar
• Ueda H, Yoshida M, Kanashima H, Nakao T, Sugiyama H, Yamane T. Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine. Gan To Kagaku Ryoho. 2014; 41:875–7.
   PubMedGoogle Scholar
• Sadashiv SK, Hilton C, Khan C, Rossetti JM, Benjamin HL, Fazal S, et al. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Med. 2014; 3:1570–8.
   PubMed Web of Science ®Google Scholar
• Manabe M, Okita J, Takakuwa T, Harada N, Aoyama Y, Kumura T, et al. Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report. Gan To Kagaku Ryoho. 2014; 41:781–4.
   PubMedGoogle Scholar
• Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol. 2014;89:795–802.
   PubMed Web of Science ®Google Scholar